OncoMatch/Clinical Trials/NCT04508790
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Is NCT04508790 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Dexamethasone and Leflunomide for recurrent plasma cell myeloma.
Treatment: Dexamethasone · Leflunomide · Pomalidomide — This phase II trial studies how well leflunomide, pomalidomide, and dexamethasone work for the treatment of multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with pomalidomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving leflunomide with pomalidomide and dexamethasone may work better in treating multiple myeloma compared to pomalidomide and dexamethasone alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
Relapsed or refractory to at least 1 prior line of therapy, including both a proteasome inhibitor and an immunomodulatory drug
Must have received: immunomodulatory drug
Relapsed or refractory to at least 1 prior line of therapy, including both a proteasome inhibitor and an immunomodulatory drug
Cannot have received: leflunomide
Prior treatment with leflunomide
Cannot have received: allogeneic transplant
Prior allogeneic transplant
Lab requirements
Blood counts
ANC >= 1.0 x 10^9/L (independent of G-CSF/GM-CSF for at least 1 week, pegylated G-CSF for at least 2 weeks); Platelets >= 75.0 x 10^9/L (independent of platelet transfusions for at least 2 weeks); Hemoglobin >= 8.0 g/dL (transfusion support allowed)
Kidney function
Creatinine clearance of >= 30 mL/min per 24 hour urine test
Liver function
Total bilirubin <= 2 X ULN (unless has Gilbert's disease); AST <= 3.5 x ULN; ALT <= 3.5 x ULN; Alkaline phosphatase < 5 x ULN
ANC >= 1.0 x 10^9/L... Platelets >= 75.0 x 10^9/L... Hemoglobin >= 8.0 g/dL... Total bilirubin <= 2 X ULN (unless has Gilbert's disease)... AST <= 3.5 x ULN... ALT <= 3.5 x ULN... Alkaline phosphatase < 5 x ULN... Creatinine clearance of >= 30 mL/min per 24 hour urine test
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify